{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:57:22Z","timestamp":1783976242925,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T00:00:00Z","timestamp":1348617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00125-012-2714-y","type":"journal-article","created":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T00:53:46Z","timestamp":1348620826000},"page":"22-30","source":"Crossref","is-referenced-by-count":37,"title":["Effects of 12\u00a0weeks\u2019 treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study"],"prefix":"10.1007","volume":"56","author":[{"given":"K. D.","family":"Hove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Br\u00f8ns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"F\u00e6rch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. E.","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Rehfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,26]]},"reference":[{"issue":"Suppl 1","key":"2714_CR1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000200100","volume":"44","author":"HP Festen","year":"1989","unstructured":"Festen HP (1989) Effects of omeprazole on gastric secretory functions. Digestion 44(Suppl 1):18\u201324","journal-title":"Digestion"},{"key":"2714_CR2","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1152\/physrev.1998.78.4.1087","volume":"78","author":"JF Rehfeld","year":"1998","unstructured":"Rehfeld JF (1998) The new biology of gastrointestinal hormones. Physiol Rev 78:1087\u20131108","journal-title":"Physiol Rev"},{"key":"2714_CR3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev.med.57.110104.115624","volume":"57","author":"LL Baggio","year":"2006","unstructured":"Baggio LL, Drucker DJ (2006) Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 57:265\u2013281","journal-title":"Annu Rev Med"},{"key":"2714_CR4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s001250050764","volume":"40","author":"RN Wang","year":"1997","unstructured":"Wang RN, Rehfeld JF, Nielsen FC, Kloppel G (1997) Expression of gastrin and transforming growth factor-alpha during duct to islet cell differentiation in the pancreas of duct-ligated adult rats. Diabetologia 40:887\u2013893","journal-title":"Diabetologia"},{"key":"2714_CR5","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1007\/s00125-010-1825-6","volume":"53","author":"TB Bodvarsdottir","year":"2010","unstructured":"Bodvarsdottir TB, Hove KD, Gotfredsen CF et al (2010) Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 53:2220\u20132223","journal-title":"Diabetologia"},{"key":"2714_CR6","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1172\/JCI107315","volume":"52","author":"JF Rehfeld","year":"1973","unstructured":"Rehfeld JF, Stadil F (1973) The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. J Clin Invest 52:1415\u20131426","journal-title":"J Clin Invest"},{"key":"2714_CR7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1172\/JCI108457","volume":"58","author":"JF Rehfeld","year":"1976","unstructured":"Rehfeld JF (1976) Disturbed islet-cell function related to endogenous gastrin release. Studies on insulin secretion and glucose tolerance in pernicious anemia. J Clin Invest 58:41\u201349","journal-title":"J Clin Invest"},{"key":"2714_CR8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1748-1716.2010.02235.x","volume":"201","author":"JF Rehfeld","year":"2011","unstructured":"Rehfeld JF (2011) Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf) 201:405\u2013411","journal-title":"Acta Physiol (Oxf)"},{"key":"2714_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mehy.2009.02.010","volume":"73","author":"IN Mefford","year":"2009","unstructured":"Mefford IN, Wade EU (2009) Proton pump inhibitors as a treatment method for type II diabetes. Med Hypotheses 73:29\u201332","journal-title":"Med Hypotheses"},{"key":"2714_CR10","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/j.diabres.2010.09.007","volume":"90","author":"KD Hove","year":"2010","unstructured":"Hove KD, Faerch K, Bodvarsdottir TB, Karlsen AE, Petersen JS, Vaag A (2010) Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients\u2014a retrospective analysis. Diabetes Res Clin Pract 90:e72\u2013e74","journal-title":"Diabetes Res Clin Pract"},{"key":"2714_CR11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4239\/wjd.v2.i12.217","volume":"2","author":"D Boj-Carceller","year":"2011","unstructured":"Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R (2011) Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2:217\u2013220","journal-title":"World J Diabetes"},{"key":"2714_CR12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3122\/jabfm.2012.01.100161","volume":"25","author":"MA Crouch","year":"2012","unstructured":"Crouch MA, Mefford IN, Wade EU (2012) Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. J Am Board Fam Med 25:50\u201354","journal-title":"J Am Board Fam Med"},{"key":"2714_CR13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/00365510701771831","volume":"68","author":"JF Rehfeld","year":"2008","unstructured":"Rehfeld JF (2008) The art of measuring gastrin in plasma: a dwindling diagnostic discipline? Scand J Clin Lab Invest 68:353\u2013361","journal-title":"Scand J Clin Lab Invest"},{"key":"2714_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000197305","volume":"8","author":"F Stadil","year":"1973","unstructured":"Stadil F, Rehfeld JF (1973) Determination of gastrin in serum. An evaluation of the reliability of a radioimmunoassay. Scand J Gastroenterol 8:101\u2013112","journal-title":"Scand J Gastroenterol"},{"key":"2714_CR15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-07-0815","volume":"158","author":"SS Lund","year":"2008","unstructured":"Lund SS, Tarnow L, Stehouwer CD et al (2008) Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 158:631\u2013641","journal-title":"Eur J Endocrinol"},{"key":"2714_CR16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7326\/0003-4819-153-6-201009210-00005","volume":"153","author":"M Charlot","year":"2010","unstructured":"Charlot M, Ahlehoff O, Norgaard ML et al (2010) Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 153:378\u2013386","journal-title":"Ann Intern Med"},{"key":"2714_CR17","doi-asserted-by":"crossref","first-page":"d2690","DOI":"10.1136\/bmj.d2690","volume":"342","author":"M Charlot","year":"2011","unstructured":"Charlot M, Grove EL, Hansen PR et al (2011) Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 342:d2690","journal-title":"BMJ"},{"key":"2714_CR18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.cgh.2009.05.021","volume":"7","author":"L Lundell","year":"2009","unstructured":"Lundell L, Miettinen P, Myrvold HE et al (2009) Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 7:1292\u20131298","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2714_CR19","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.2011.626","volume":"305","author":"JP Galmiche","year":"2011","unstructured":"Galmiche JP, Hatlebakk J, Attwood S et al (2011) Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 305:1969\u20131977","journal-title":"JAMA"},{"key":"2714_CR20","unstructured":"FDA (2007) FDA\u2019s safety reviews of prilosec and nexium find no evidence of increased rates of cardiac events. Available from www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2007\/ucm109037.htm . Accessed 20 Aug 2012"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-012-2714-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-012-2714-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-012-2714-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T06:01:23Z","timestamp":1562220083000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-012-2714-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,26]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["2714"],"URL":"https:\/\/doi.org\/10.1007\/s00125-012-2714-y","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,26]]}}}